ReviewCold Spring Harbor perspectives in medicine2012
Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Multiple low dose streptozotocin-induced diabetes as a model for studying autoimmune diabetes in humans.Animal models and experimental medicine · 2025Review
- The Role of Intestinal Microbiota and Immune System Interactions in Autoimmune Diseases.ImmunoTargets and therapy · 2025Review
- Perspectives of patients with type 1 and type 2 diabetes on barriers to diabetes care: a qualitative study.BMC health services research · 2024Article
- miR-146a-5p mediates inflammation-induced β cell mitochondrial dysfunction and apoptosis.The Journal of biological chemistry · 2024Article
- miR-146a-5p mediates inflammation-induced β cell mitochondrial dysfunction and apoptosis.bioRxiv : the preprint server for biology · 2024Article
- Profiling of T cell repertoire in peripheral blood of patients from type 2 diabetes with complication.BMC immunology · 2024Article
- Islet Autoantibodies to Pancreatic Insulin-Producing Beta Cells in Adolescent and Adults with Type 1 Diabetes Mellitus: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2023Article
- Magnetic Particle Imaging of Transplanted Human Islets Using a Machine Learning Algorithm.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Immunological markers in type 1 diabetes mellitus in Thi-Qar province, southern Iraq.Journal of medicine and life · 2022Article
- Association between Pediatric Adenovirus Infection and Type 1 Diabetes.Children (Basel, Switzerland) · 2022Article
- Article
- An Overview on Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases.Iranian journal of pharmaceutical research : IJPR · 2019Review
- T Cell Receptor Profiling in Type 1 Diabetes.Current diabetes reports · 2017Review
- Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes.Clinical immunology (Orlando, Fla.) · 2017Article
- Comparative and correlative assessments of cytokine, complement and antibody patterns in paediatric type 1 diabetes.Clinical and experimental immunology · 2017Article
- Article
- Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile.Proteomics · 2016Article
- Article
- Combination immunotherapies for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2015Review
- Diabetes Associated Metabolomic Perturbations in NOD Mice.Metabolomics : Official journal of the Metabolomic Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes (T1D), also known as insulin-dependent diabetes mellitus, is a chronic disorder that results from autoimmune destruction of insulin-producing β cells in the islets of Langerhans within the pancreas ( Atkinson and Maclaren 1994). This disease becomes clinically apparent only after significant destruction of the β-cell mass, which reduces the ability to maintain glycemic control and metabolic function. In addition, it continues for years after clinical onset until, generally, there is complete destruction of insulin secretory capacity. Because prevention and therapy strategies are targeted to this pathologic process, it becomes imperative to have methods with which it can be monitored. This work discusses current research-based approaches to monitor the autoimmunity and metabolic function in T1D patients and their potential for widespread clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.